Related Experiment Video
Updated: Jun 26, 2026
Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
Published on: August 9, 2019
Efficacy of plerixafor in CD34+ stem cell mobilization in healthy pediatric stem cell donors
Rishab Bharadwaj1, Vimal Kumar1, Deepti Sachan2
1Department of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Dr. Rela Institute and Medical Centre, Chennai, Tamil Nadu, India.
Insights
Adding plerixafor (a CXCR4 antagonist) to granulocyte colony-stimulating factor (G-CSF) effectively mobilizes stem cells in pediatric donors. This approach ensures adequate stem cell collection for hematopoietic stem cell transplants (HSCT) with minimal adverse effects.
Area of Science:
- Hematology
- Pediatric Medicine
- Transplantation Immunology
Background:
- Allogeneic hematopoietic stem cell transplants (HSCT) require efficient stem cell collection from pediatric donors, which presents a significant challenge.
- Plerixafor, a CXCR4 antagonist, has shown promise in augmenting standard stem cell mobilization regimens.
Purpose of the Study:
- To evaluate the safety and efficacy of a single dose of plerixafor combined with G-CSF in healthy pediatric stem cell donors.
- To assess the impact of this combined regimen on stem cell mobilization and collection for HSCT.
Main Methods:
- Retrospective review of data from 14 pediatric stem cell donors.
- Donors received a standard mobilization regimen of G-CSF plus a single dose of plerixafor.
- Analysis of safety and stem cell collection efficiency.
Main Results:
- Plerixafor was well-tolerated by all pediatric donors, with no major adverse events reported.
- Robust peripheral blood stem cell mobilization was observed in all donors.
- Adequate stem cell collection was achieved in a single apheresis procedure, even with unfavorable donor/patient body weight ratios.
Conclusions:
- The combination of plerixafor and G-CSF is a safe and effective strategy for stem cell mobilization in pediatric donors.
- Plerixafor can optimize apheresis outcomes, facilitating successful HSCT procedures.
Background And Objectives:
Efficient stem cell collection from pediatric donors is a common challenge for allogeneic hematopoietic stem cell transplants (HSCT). The addition of plerixafor, a CXCR4 antagonist to standard stem cell mobilization regimens has shown success. We describe our experience with the usage of a single dose of plerixafor in addition to granulocyte colony-stimulating factor (G-CSF) in healthy pediatric stem cell donors for patients undergoing HSCT.
Materials And Methods:
A retrospective review of the safety and efficacy of plerixafor, used in pediatric stem cell donors for aiding stem cell mobilization, was done. Data from 14 pediatric donors who received plerixafor in addition to standard G-CSF were studied.
Results:
Plerixafor was well tolerated by all donors with no major adverse effects. All donors showed robust peripheral blood stem cell mobilization, enabling an adequate stem cell collection with single apheresis, even in scenarios with an unfavorable donor/patient body weight ratio.
Conclusion:
The use of plerixafor can be encouraged in pediatric donors to optimize apheresis outcomes.
More Related Videos
11:59Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
12:03Generation of Human Induced Pluripotent Stem Cells from Peripheral Blood Using the STEMCCA Lentiviral Vector
Published on: October 31, 2012
